In 2021, Kamada acquired CYTOGAM from its previous owner, and in 2023 the company received approval from the U.S. Food and Drug Administration for the manufacturing of the product.

DETROIT, MICHIGAN - June 6, 2025 (NEWMEDIAWIRE) - Cytomegalovirus (CMV) is a common virus that most adults are exposed to at some point in their lives, and over half of American adults have been ...

Cytogam® is contraindicated in individuals with a history of a prior severe reaction associated with the administration of this or other human immunoglobulin preparations.

Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated ...

REHOVOT, Israel and HOBOKEN, N.J., June 17, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated ...

REHOVOT, Israel and HOBOKEN, N.J., June 17, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company wi ...

Kamada Announces Launch of a Comprehensive Post-Marketing Research Program for CYTOGAM® Program Aimed at Generating Key Data in Support of the Benefits of CYTOGAM® in the Management of Cytomegalovirus ...

Kamada Ltd., a global biopharmaceutical company, is addressing this challenge head-on by increasing efforts to promote CYTOGAM, its CMV immune globulin, and launching a post-marketing research program ...